Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1Lymphopenia 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Gemcitabine 20Cisplatin 13Paclitaxel 8Carboplatin 8Docetaxel 5Radiotherapy 4Doxorubicin 4aflibercept 3Vinblastine 3Ramucirumab 3Methotrexate 3Fluorouracil 3vinflunine 2pembrolizumab 2Trastuzumab 2Sunitinib 2Platinum 2Neoadjuvant Therapy 2Ifosfamide 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tipifarnib 1temsirolimus 1rubitecan 1piritrexim 1pegfilgrastim 1pazopanib 1lonafarnib 1ixabepilone 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urethral Neoplasms × Interleukin-7 × Clear all
NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡